Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012350 · ClinicalTrials.gov registry record · Phase 2
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00012350 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 44 participants.
The verdict
NCT00012350, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed or refractory multiple myeloma.
Interventions
- DRUG FTI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2001-01 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012350
The ClinicalTrials.gov registry entry for NCT00012350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FTI is the first listed.
NCT00012350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012350 about?
NCT00012350 is a clinical study titled "Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed or refractory multiple myeloma.
What is the current status of trial NCT00012350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2001-01. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00012350?
The interventions under investigation include: FTI (DRUG).
Who is sponsoring clinical trial NCT00012350?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.